『Breast Cancer Update』のカバーアート

Breast Cancer Update

Breast Cancer Update

著者： Dr. Neil Love
無料で聴く

Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology-oncology fellows ongoing access to the perspectives and opinions of national and international breast cancer clinical investigators.Copyright 2025 Research To Practice. All Rights Reserved 科学 衛生・健康的な生活 身体的病い・疾患
エピソード
  • Breast Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting on the Use of Oral SERDs and Agents Targeting the PI3K/AKT/mTOR Pathway

    Breast Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting on the Use of Oral SERDs and Agents Targeting the PI3K/AKT/mTOR Pathway
    2026/07/25

    Featuring perspectives from Dr Sara A Hurvitz, Dr Erica Mayer, Dr Joyce O’Shaughnessy, Dr Sara M Tolaney and Dr Nicholas Turner, moderated by Dr Tolaney, including the following topics:

    • Introduction (0:00)
    • Current and Future Roles of Agents Targeting the PI3K/AKT/mTOR Pathway and Oral Selective Estrogen Receptor Degraders (SERDs) in First-Line Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) — Dr Turner (2:35)
    • Role of Oral SERD Monotherapy in the Treatment of Progressive HR-Positive, HER2-Negative mBC — Dr O’Shaughnessy (25:23)
    • Potential Use of Oral SERD-Containing Combination Regimens in Managing Progressive HR-Positive, HER2-Negative mBC — Dr Mayer (46:29)
    • Clinical Utility of Agents Targeting the PI3K/AKT/mTOR Pathway for Patients with Progressive HR-Positive, HER2-Negative mBC — Dr Hurvitz (1:07:06)
    • Potential Use of Oral SERDs for HR-Positive, HER2-Negative Localized Breast Cancer — Dr Tolaney (1:38:17)

    CME information and select publications
    続きを読む 一部表示
    1 時間 58 分
  • HER2-Positive Metastatic Breast Cancer — An Interview with Prof Dr Sibylle Loibl on First-Line and Maintenance Therapy

    HER2-Positive Metastatic Breast Cancer — An Interview with Prof Dr Sibylle Loibl on First-Line and Maintenance Therapy
    2026/07/18

    Featuring an interview with Prof Dr Sibylle Loibl, including the following topics:

    • Perspectives on overall survival gains achieved over the years for patients with metastatic breast cancer (mBC) (0:00)
    • Previous treatment and patient outcomes in the DESTINY-Breast09 trial of trastuzumab deruxtecan (T-DXd) with or without pertuzumab (5:35)
    • Role of endocrine therapy in the treatment of hormone receptor-positive, HER2-positive mBC (8:01)
    • Targeting the PI3K signaling pathway in HER2-positive mBC (11:08)
    • Contraindications for T-DXd; T-DXd-associated gastrointestinal toxicities and interstitial lung disease (13:53)
    • Optimal duration of and therapeutic partner for T-DXd as first-line maintenance therapy for patients with HER2-positive mBC (20:44)
    • Case: A woman in her early 40s with metastatic relapse of HER2-positive breast cancer 2 years after completing neoadjuvant and adjuvant therapy (26:54)
    • Role of exercise and weight control in the management of breast cancer; effect of pregnancy on the breast tumor immune environment (40:03)

    CME information and select publications
    続きを読む 一部表示
    46 分
  • Localized HR-Positive Breast Cancer — Year in Review Series on Relevant New Datasets and Advances

    Localized HR-Positive Breast Cancer — Year in Review Series on Relevant New Datasets and Advances
    2026/07/13

    Featuring perspectives from Dr Harold J Burstein and Dr Joyce O’Shaughnessy, including the following topics:

    • Introduction: ODAC — April 30, 2026 (00:00)
    • Adjuvant CDK4/6 Inhibitors (13:03)
    • Adjuvant Oral Selective Estrogen Receptor Degraders (21:53)
    • Premenopausal Patients (30:52)
    • Duration of Adjuvant Endocrine Treatment (38:44)
    • Genomic Predictors of Chemotherapy Benefit (47:19)
    • Neoadjuvant Treatment (55:13)

    CME information and select publications
    続きを読む 一部表示
    58 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません